Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

LTI-03 is formulated as a dry powder inhalation therapy that's designed to help ease fibrosis and symptoms of idiopathic ...

Columnist Sam Kirton pays tribute to his friend and IPF mentor, Pieter van den Assum, who passed away on May 17.

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

One of my frustrations as a pulmonary fibrosis patient is finding solid information about what to expect as my PF progresses. I’ve asked several doctors what to expect during the end stage of PF, but ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...